139 related articles for article (PubMed ID: 6914809)
1. Isolation and properties of a complement inhibitor from Naja haje venom, distinct from known anticomplementary factors in cobra venom.
von Zabern I; Przyklenk H; Damerau B; Zimmermann B
Scand J Immunol; 1981 Aug; 14(2):109-20. PubMed ID: 6914809
[TBL] [Abstract][Full Text] [Related]
2. [Major complement inhibiting factors from the venom of the Central Asian cobra Naja naja oxiana].
Kozlov LV; Shoĭbonov BB; Antonov VK
Biokhimiia; 1989 Nov; 54(11):1919-26. PubMed ID: 2627558
[TBL] [Abstract][Full Text] [Related]
3. Oxiagin from the Naja oxiana cobra venom is the first reprolysin inhibiting the classical pathway of complement.
Shoibonov BB; Osipov AV; Kryukova EV; Zinchenko AA; Lakhtin VM; Tsetlin VI; Utkin YN
Mol Immunol; 2005 Jun; 42(10):1141-53. PubMed ID: 15829304
[TBL] [Abstract][Full Text] [Related]
4. [A new low molecular-weight protein effector of human complement from the venom of the Central Asian cobra Naja naja oxiana].
Kozlov LV; Soliakov LS; Zinchenko AA
Bioorg Khim; 1984 Mar; 10(3):323-32. PubMed ID: 6567467
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage.
von Zabern I; Hinsch B; Przyklenk H; Schmidt G; Vogt W
Immunobiology; 1980 Dec; 157(4-5):499-514. PubMed ID: 6905795
[TBL] [Abstract][Full Text] [Related]
6. A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor.
O'Keefe MC; Caporale LH; Vogel CW
J Biol Chem; 1988 Sep; 263(25):12690-7. PubMed ID: 3045125
[TBL] [Abstract][Full Text] [Related]
7. [Complement-inhibiting acidic factors from the venom of Central Asian cobra Naja naja oxiana].
Shobonov BB; Kozlov LV; Antonov VK
Biokhimiia; 1989 Dec; 54(12):2054-60. PubMed ID: 2633805
[TBL] [Abstract][Full Text] [Related]
8. Preparation of complement fragments C3b and C3a from purified rat complement component C3 by activated cobra venom factor.
Usami M; Ohno Y
J Pharmacol Toxicol Methods; 2005; 52(2):260-3. PubMed ID: 16125624
[TBL] [Abstract][Full Text] [Related]
9. An improved method for the isolation from Naja naja venom of cobra factor (CoF) free of phospholipase A.
Pepys MB; Tompkins C; Smith AD
J Immunol Methods; 1979; 30(2):105-17. PubMed ID: 574149
[TBL] [Abstract][Full Text] [Related]
10. Chain structure of cobra venom factor from Naja naja and Naja haje venom.
von Zabern I; Przyklenk H; Vogt W
Scand J Immunol; 1982 Apr; 15(4):357-62. PubMed ID: 7100817
[TBL] [Abstract][Full Text] [Related]
11. Purification from Vipera lebetina (desert adder) venom of a protein that depletes human complement.
Gasmi A; Louzir H; Karoui H; el Ayeb M; Dellagi K
Nat Toxins; 1994; 2(1):44-8. PubMed ID: 8032695
[TBL] [Abstract][Full Text] [Related]
12. Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro.
Brown EJ; Joiner KA; Frank MM
J Clin Invest; 1983 Jun; 71(6):1710-9. PubMed ID: 6863540
[TBL] [Abstract][Full Text] [Related]
13. Complement 1 inhibitor is a regulator of the alternative complement pathway.
Jiang H; Wagner E; Zhang H; Frank MM
J Exp Med; 2001 Dec; 194(11):1609-16. PubMed ID: 11733575
[TBL] [Abstract][Full Text] [Related]
14. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1977 Jul; 146(1):257-70. PubMed ID: 301546
[TBL] [Abstract][Full Text] [Related]
15. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
[TBL] [Abstract][Full Text] [Related]
16. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje.
Van den Berg CW; Aerts PC; Van Dijk H
J Immunol Methods; 1991 Feb; 136(2):287-94. PubMed ID: 1999656
[TBL] [Abstract][Full Text] [Related]
17. Effects of iodipamide on human C3 and factor B in vitro.
Durda PJ; Pagano RJ; Bauman N; Brockman JA
J Allergy Clin Immunol; 1982 Nov; 70(5):353-60. PubMed ID: 6922882
[TBL] [Abstract][Full Text] [Related]
18. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
19. Purification and characterization of anticomplement factor (cobra venom factor) from the Naja naja atra venom.
Takahashi H; Hayashi K
Biochim Biophys Acta; 1982 Feb; 701(1):102-10. PubMed ID: 6173071
[TBL] [Abstract][Full Text] [Related]
20. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement).
Alper CA; Balavitch D
Science; 1976 Mar; 191(4233):1275-6. PubMed ID: 56780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
